Kevin Norrett Biography and Net Worth

COO of Codexis

Mr. Norrett brings over two decades of experience across commercial strategy, business operations and corporate development for both established and emerging biotechnology companies. Most recently, he served as Chief Business Officer of Sierra Oncology. There, he led commercial operations and corporate development and communications and completed the $1.9 billion acquisition by GSK. Prior to Sierra Oncology, Mr. Norrett was Chief Commercial Officer at Angion Biomedica, setting commercial strategy and positioning for its pipeline and its successful IPO. Previously, he served as Vice President of Marketing, Market Access and Commercial Operations at Aimmune Therapeutics, acquired by Nestle Health Science, where he built commercial operations for the launch of Palforzia®, the first approved therapy for pediatric peanut allergy. Prior to joining Aimmune, Mr. Norrett was Vice President, Market Access and Commercial Development at ZS Pharma, acquired by AstraZeneca for $2.7 billion. Mr. Norrett also held increasingly senior commercial leadership roles at Exelixis and Genentech, where he launched multiple products across oncology and rare disease. Kevin also served as an Associate in SG Cowen’s Health Care Investment Banking Group, closing over 20 transactions worth over $2 billion. Mr. Norrett earned an MBA from the Haas School of Business at the University of California, Berkeley, an MS in Biochemistry and Molecular Biology from University of California, Los Angeles and a BS in Biological Sciences from the University of California, Davis.

What is Kevin Norrett's net worth?: The estimated net worth of Kevin Norrett is at least $173.64 thousand as of September 11th, 2023. Mr. Norrett owns 98,102 shares of Codexis stock worth more than $173,641 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Norrett may own. Additionally, Mr. Norrett receives a salary of $739,560.00 as COO at Codexis. Learn More about Kevin Norrett's net worth.
How old is Kevin Norrett?: Mr. Norrett is currently 51 years old. There are 3 older executives and no younger executives at Codexis. The oldest executive at Codexis is Dr. Stephen George Dilly MBBS, Ph.D., President, CEO & Director, who is 64 years old. Learn More on Kevin Norrett's age.
What is Kevin Norrett's salary?: As the COO of Codexis, Inc., Mr. Norrett earns $739,560.00 per year. There are 2 executives that earn more than Mr. Norrett. The highest earning executive at Codexis is Dr. Stephen George Dilly MBBS, Ph.D., President, CEO & Director, who commands a salary of $1,880,000.00 per year. Learn More on Kevin Norrett's salary.
How do I contact Kevin Norrett?: The corporate mailing address for Mr. Norrett and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Kevin Norrett's contact information.
Has Kevin Norrett been buying or selling shares of Codexis?: Kevin Norrett has not been actively trading shares of Codexis within the last three months. Most recently, on Monday, September 11th, Kevin Norrett bought 9,000 shares of Codexis stock. The stock was acquired at an average cost of $1.72 per share, with a total value of $15,480.00. Following the completion of the transaction, the chief operating officer now directly owns 98,102 shares of the company's stock, valued at $168,735.44. Learn More on Kevin Norrett's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Kevin Norrett (COO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, insiders at the biotechnology company sold shares 2 times. They sold a total of 12,478 shares worth more than $31,257.39. The most recent insider tranaction occured on October, 13th when insider Alison Moore sold 6,239 shares worth more than $15,659.89. Insiders at Codexis own 1.9% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 10/13/2025.

Kevin Norrett Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/11/2023	Buy	9,000	$1.72	$15,480.00	98,102
3/7/2023	Sell	8,596	$4.60	$39,541.60	97,360

Kevin Norrett Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $1.77

$1.67

$1.78

50 Day Range

MA: $2.18

$1.54

$2.76

2 Week Range

Now: $1.77

$1.52

$6.08

Volume

700,912 shs

Average Volume

1,512,230 shs

Market Capitalization

$159.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Kevin Norrett Biography and Net Worth

What is Kevin Norrett's net worth?

How old is Kevin Norrett?

What is Kevin Norrett's salary?

How do I contact Kevin Norrett?

Has Kevin Norrett been buying or selling shares of Codexis?

Who are Codexis' active insiders?

Are insiders buying or selling shares of Codexis?